TALTZ (Eli Lilly Australia Pty Ltd)
Product name
TALTZ
Sponsor
Date registered
Evaluation commenced
Decision date
Approval time
180 working days (255)
Active ingredients
ixekizumab
Registration type
EOI
Indication
TALTZ (injection) is now also indicated for the treatment of active psoriatic arthritis in adult patients who have responded inadequately, or who are intolerant, to previous DMARD therapy. Taltz may be used as monotherapy or in combination with a conventional DMARD (e.g.methotrexate).